IFN-γ和IL-4在结直肠癌组织中的表达及与临床分期的关系

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (594 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨结直肠癌组织中辅助性T（Th）1细胞因子γ干扰素（IFN-γ）与Th2细胞因子白细胞介素-4（IL-4）的表达情况及与患者临床分期的关系。方法收集2016年1月—2018年8月湖南医药学院第一附属医院收治的61例结直肠癌患者的肠组织标本为结直肠癌组，依据临床分期将其分为临床Ⅰ期（16例），临床Ⅱ期（20例），临床Ⅲ期（15例），临床Ⅳ期（10例）。另收集各期患者距离癌组织边缘外10 cm的癌旁组织各5例（共20例）作为对照组。免疫组织化学法检测不同分期患者组织中IFN-γ和IL-4的表达情况，分析每组阳性染色部分的平均积分光密度值（MIOD），比较各组间IFN-γ和IL-4的表达。结果肿瘤分期越高，IFN-γ表达的阳性程度越弱；肿瘤分期越高，IL-4的阳性越强。临床Ⅳ期结直肠癌组织IL-4 MIOD值高于临床Ⅰ~Ⅲ期及对照组，临床Ⅱ、Ⅲ期结直肠癌组织IL-4 MIOD值高于临床Ⅰ期及对照组，临床Ⅰ期结直肠癌组织IL-4 MIOD值高于对照组，差异均有统计学差异（均P < 0.05）；临床Ⅳ期结直肠癌组织IFN-γ MIOD值低于临床Ⅰ~Ⅲ期及对照组，临床Ⅲ期结直肠癌组织IFN-γ MIOD值低于Ⅰ~Ⅱ期及对照组，临床Ⅱ期结直肠癌组织IFN-γ MIOD值低于Ⅰ期及对照组，临床Ⅰ期结直肠癌组织IFN-γ MIOD值低于对照组，差异均有统计学差异（均P < 0.05）。结论结直肠癌组织中细胞因子IFN-γ的表达减少，IL-4的表达增加，且与患者临床分期密切相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	方贤磊1
	2 曾丽平1
	2 李娜1 向莎2 伍世挥2 卢小敏2 张畅1
	2 梁露1

关键词 ：干扰素-&gamma, 白细胞介素-4, 结直肠癌, 临床分期

Abstract：Objective To investigate the expression of T helper (Th)1 cytokine interferon-γ (IFN-γ) and Th2 cytokine interleukin-4 (IL-4) in colorectal cancer tissues and explore its relationship with clinical stage. Methods The intestinal tissue samples of 61 patients with colorectal cancer admitted to the First Affiliated Hospital of Hu′nan University of Medicine from January 2016 to August 2018 were collected as colorectal cancer group. According to the clinical stage, they were devided into clinical stage Ⅰ (16 cases)， clinical stage Ⅱ (20 cases)， clinical stage Ⅲ (15 cases)， clinical stage Ⅳ (10 cases). In addition, 5 cases (20 cases in total) of paracancer tissues 10 cm away from the edge of the cancer tissues were collected as the control group. The immunohistochemistry was used to detect the expression of IFN-γ and IL-4 in tissues. Then the mean integrated optical density (MIOD) of the positive staining fraction of each group was analyzed, and the expression differences of IFN-γ and IL-4 among all groups were compared. Results The higher the tumor stage, the weaker the positive degree of IFN-γ expression. The higher the tumor stage, the stronger the IL-4 positive. IL-4 MIOD value in clinical stage Ⅳ colorectal cancer tissue was higher than that in clinical stageⅠ-Ⅲ and the control group, IL-4 MIOD values in the clinical stage Ⅱ-Ⅲ colorectal cancer tissue were higher than those in clinical stage Ⅰ and the control group, IL-4 MIOD value in the clinical stage Ⅰ colorectal cancer tissue was higher than that in the control group, and the differences were statistically significant (all P < 0.05). IFN-γ MIOD value in clinical stage Ⅳ colorectal cancer tissue was lower than that in the clinical stage Ⅰ-Ⅲ and the control group, IFN-γ MIOD value in the clinical stage Ⅲ colorectal cancer tissue was lower than that in the clinical stage Ⅰ-Ⅱ and the control group, IFN-γ MIOD value in the clinical Ⅱ colorectal cancer tissue was lower than that in the clinical stage Ⅰ and the control group, IFN-γ MIOD value in the clinical stage Ⅰ colorectal cancer tissue was lower than that in the control group, and the differences were statistically significant (all P < 0.05). Conclusion The expression of cytokine IFN-γ is decreased in colorectal cancer tissues, and the expression of IL-4 is increased, which are closely related to the clinical pathological stage of patients.

Key words： Interferon-γ Interleukin-4 Colorectal cancer Clinical stage

基金资助:湖南省教育厅科学研究项目一般项目（16C1144、17C1140）。

通讯作者: 梁露（1982-），女，副主任医师；研究方向：肿瘤病理诊断与发病机制。

作者简介: 方贤磊（1989-），男，硕士；研究方向：肿瘤病理诊断与发病机制。

引用本文:

方贤磊1,2 曾丽平1,2 李娜1 向莎2 伍世挥2 卢小敏2 张畅1,2 梁露1. IFN-γ和IL-4在结直肠癌组织中的表达及与临床分期的关系[J]. 中国医药导报, 2020, 17(32): 17-19,28.
FANG Xianlei1,2 ZENG Liping1,2 LI Na1 XIANG Sha2 WU Shihui2 LU Xiaomin2 ZHANG Chang1,2 Liang LU1. Expression of IFN-γ and IL-4 in colorectal cancer and their relationship with clinical stage. 中国医药导报, 2020, 17(32): 17-19,28.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I32/17

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Razi S，BaradaranNoveiry B，Keshavarz-Fathi M，et al. IL-17 and colorectal cancer：From carcinogenesis to treatment [J]. Cytokine，2019，116：7-12.
[3] Rager JE，Suh M，Chappell GA，et al. Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis [J]. Toxicol Lett，2019，305：40-50.
[4] Jinesh GG，Sambandam V，Vijayaraghavan S，et al. Molecular genetics and cellular events of K-Ras-driven tumorigenesis [J]. Oncogene，2018，37（7）：839-846.
[5] Kumar S，Saini RV，Mahindroo N. Recent advances in cancer immunology and immunology-based anticancer therapies [J]. Biomed Pharmacother，2017，96：1491-1500.
[6] Han HS，Shin JS，Song YR，et al. Immunostimulatory effects of polysaccharides isolated from young barley leaves （Hordeum vulgare L.） with dual activation of Th1 and Th2 in splenic T cells and cyclophosphamide-induced immunosuppressed mice [J]. Int J Biol Macromol，2020， 147：954-964.
[7] Safar HA，Mustafa AS，Amoudy HA，et al. The effect of adjuvants and delivery systems on Th1，Th2，Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins [J]. PLoS One，2020，15（2）：e0228381.
[8] Lin W，Niu Z，Zhang H，et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer [J]. Int J Clin Exp Pathol，2019，12（9）：3604-3612.
[9] Zhao X，Liu J，Ge S，et al. Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance [J]. Front Pharmacol，2019，10：624.
[10] Lee HL，Jang JW，Lee SW，et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization [J]. Sci Rep，2019，9（1）：3260.
[11] Kaur RP，Vasudeva K，Singla H，et al. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer [J]. J Cell Physiol，2018，233（12）：9716-9723.
[12] Chen F，Li X，Wang J，et al. Combination of Ginsenoside H dripping pills and cyclophosphamide improve paraneoplastic syndrome and inhibit postoperative recurrence via the reversion of Th1/Th2 shift [J]. Biomed Pharmacother，2018，108：865-875.
[13] 王琰，卢斌峰，蒋敬庭.肿瘤浸润淋巴细胞及其亚群在肿瘤免疫中的作用[J].临床检验杂志，2018，36（11）：854-857.
[14] Witonsky S，Buechner-Maxwell V，Santonastasto A，et al. Can levamisole upregulate the equine cell-mediated macrophage（M1）dendritic cell（DC1）T-helper 1（CD4 Th1）T-cytotoxic（CD8）immune response in vitro? [J]. J Vet Intern Med，2019，33（2）：889-896.
[15] Walker JA，McKenzie ANJ. TH2 cell development and function [J]. Nat Rev Immunol，2018，18（2）：121-133.
[16] Gonzalez-Gugel E，Saxena M，Bhardwaj N. Modulation of innate immunity in the tumor microenvironment [J]. Cancer Immunol Immunother，2016，65（10）：1261-1268.
[17] Wang CY，Ding HZ，Tang X，et al. Comparative analysis of immune function，hemorheological alterations and prognosis in colorectal cancer patients with different traditional Chinese medicine syndromes [J]. Cancer Biomark，2018，21（3）：701-710.
[18] Tosolini M，Kirilovsky A，Mlecnik B，et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells（Th1，Th2，Treg，Th17）in patients with colorectal cancer [J]. Cancer Res，2011，71（4）：1263-1271.
[19] 王静，徐向上，曹志新，等.Th细胞因子在结直肠癌组织中的表达[J].中华实验外科杂志，2010（1）：62-64.
[20] 黄家豪，曹云飞，高枫.结直肠癌患者外周血Th1和Th2细胞的检测与临床意义[J].结直肠肛门外科，2012，18（2）：71-79.